Comparison of the Effect of Statin Types on the Reduction of Lipid Profile and Hs-Crp Inflammatory Marker in Diabetics with Dyslipidemia  

Oleh:

Ayumuyas, Nur Palestin ; Dorotea, Debra ; Suprapti, Budi ; Wibisono, Sony

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Folia Medica Indonesiana vol. 51 no. 2 (2015), page 86-90.
Topik: simvastatin; atorvastatin; lipid; Hs-CRP; diabetes; dyslipidemia
Fulltext: download-fullpapers-fmi9841c052b8full.pdf (50.71KB)

Isi artikel

Elevated inflammation marker C-reactive protein (CRP) is commonly associated with cardiovascular disease. Statins inhibit the enzyme HMG-CoA reductase, which is required for cholesterol biosynthesis and might also exert pleiotropic effects so that beneficial in the prevention of cardiovascular disease. All statins have the same mechanism of action but different in chemical structures, pharmacokinetic profiles, and lipid reducing efficacy. The objective of this study was to compare the efficacy of two statins, atorvastatin and simvastatin to reduce the lipid profiles and inflammation marker Hs-CRP in patient diabetes mellitus type 2 with dyslipidemic. This was a prospective cohort observational study of 18 diabetes dyslipidemia patient taking either simvastatin 20 mg (n = 11 patient) and atorvastatin 10 mg (n = 7 patient) for about 6 weeks. The efficacy of therapy measured by lipid profiles (total cholesterol, LDL-C and triglyceride) and inflammation marker Hs-CRP. After 6 weeks therapy, lipid profile and inflammation marker Hs-CRP pre and post therapy of either taking simvastatin 20 mg or atorvastatin 10 mg did not shown the significance different (p > 0.05). There were also no significance different in lipid profiles between the two groups. In the other hand, the inflammation marker Hs-CRP serum of atorvastatin group significantly decrease compared to simvastatin group (p < 0.05). In conclusion, there were no different in reducing lipid profiles (total cholesterol, LDL-C, and triglyceride) in either patient taking atorvastatin 10 mg or simvastatin 20 mg after six weeks therapy. Atorvastatin decrease the inflammation marker Hs-CRP serums better than simvastatin. (FMI 2015;51:86-90)

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali